Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™Business Wire • 01/18/23
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering EffortsBusiness Wire • 01/10/23
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)Business Wire • 01/04/23
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)Business Wire • 12/14/22
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of PainBusiness Wire • 08/24/22
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent DevelopmentsBusiness Wire • 08/15/22
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with OsteoarthritisBusiness Wire • 06/27/22
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceBusiness Wire • 05/19/22
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent DevelopmentsBusiness Wire • 05/16/22
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical ResearchBusiness Wire • 05/05/22
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing AgreementBusiness Wire • 03/15/22
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19Business Wire • 02/15/22
Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic PainBusiness Wire • 02/10/22
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the KneeBusiness Wire • 01/21/22
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™Business Wire • 01/18/22
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the KneeBusiness Wire • 12/20/21